This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Patient Preferences for HR+/HER2- Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment.
Breast care (Basel, Switzerland) · 2025
Latest funding
Incretin-mimetic drugs for cancer prevention: Mechanisms and clinical potential
CIHR · 2025 · Principal investigator
1 publications.
Patient Preferences for HR+/HER2- Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment.
Harmer V, Ammendolea C, Ryan M, Boyle F, Werutsky G, El Mouzain D, Marshall DA, Thomas C, Heidenreich S, Lu H, Krucien N, Payan JM, Aubel D, Danyliv A, Pathak P, Harbeck N
Incretin-mimetic drugs for cancer prevention: Mechanisms and clinical potential
Principal investigators: Pollak, Michael N; Ammendolea, Cathy; Azoulay, Laurent; Muller, William J
Keywords: Biomarkers; Cancer Prevention; Mechanisms; Obesity; Pharmacoepidemiology; Semaglutide; Tirzepatide
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.